MedTrace Logo

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04326283 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-05-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.

Conditions

Interventions

DRUG

Trametinib (0.5 mg)

0.5 mg/day

DRUG

Trametinib (1 mg)

1 mg/day

DRUG

Riluzole (100 mg)

100 mg/day (50 mg twice)

Sponsors & Collaborators

  • Genuv Inc.

    lead INDUSTRY

Principal Investigators

  • Byoung Joon Kim · Samsung Medical Center, Seoul, Republic of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-02
Primary Completion
2023-04-28
Completion
2023-04-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04326283 on ClinicalTrials.gov